HC Wainwright & Co. Initiates Coverage On Oyster Point Pharma with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Matthew Caufield initiates coverage on Oyster Point Pharma (NASDAQ:OYST) with a Buy rating and announces Price Target of $20.